Edgewood Oncology, Inc.
1 known investors
Find your way into Edgewood Oncology, Inc.
Sign up to see every warm intro you have to Edgewood Oncology, Inc.
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Edgewood Oncology, Inc. team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class treatment candidate for hematologic malignancies and genetically-defined solid tumors. The company focuses on addressing unmet medical needs in cancer treatment.
Founders & leadership
YB

Yinon Ben-NeriahScientific Founder
DN

David N. CookChief Executive OfficerDavid N. Cook is Chief Executive Officer of Edgewood Oncology, a clinical-stage biotechnology company developing therapies for hematologic malignancies and genetically-defined solid tumors. He has held senior executive roles in biotechnology product development across microbiome therapeutics, vaccines, small molecules, and biologics, with experience spanning discovery research, clinical trials, regulatory affairs, and manufacturing, and has obtained EU marketing authorizations for multiple novel medical products.
Investors · 1
Frequently asked questions
- What does Edgewood Oncology, Inc. do?
- Edgewood Oncology is a clinical-stage biotechnology company developing BTX-A51, a first-in-class treatment candidate for hematologic malignancies and genetically-defined solid tumors. The company focuses on addressing unmet medical needs in cancer treatment.
- Who founded Edgewood Oncology, Inc.?
- Edgewood Oncology, Inc. was founded by Yinon Ben-Neriah.
- Who are Edgewood Oncology, Inc.'s investors?
- Edgewood Oncology, Inc.'s investors include Alta Partners.

